Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Circulating and brain-resident memory CD8+ T cells seed distinct bystander T <sub>RM</sub> -like populations in glioblastoma.

bioRxiv : the preprint server for biology·2026

Same author

Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Prostate Cancer Presenting With Isolated Mediastinal Metastasis: A Case Report.

Cureus·2026

Same author

Correction to: 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency Management Committee.

Circulation. Cardiovascular imaging·2026

Same author

Conducting multicenter trials through the trial innovation network comprehensive consultation.

Contemporary clinical trials·2026

Same author

Cerebellar acceleration of learning in an evidence-accumulation task.

Cell reports·2026

Same journal

Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.

Archives of pathology & laboratory medicine·2026

Same journal

Cross-Reactivity of TPIT Antibody Clone OTI2G1 in Chordoma: Structural Mechanisms and Diagnostic Implications.

Archives of pathology & laboratory medicine·2026

Same journal

Paracoccidioidomycosis at Autopsy: A Case Series and Literature Review.

Archives of pathology & laboratory medicine·2026

Same journal

Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program.

Archives of pathology & laboratory medicine·2026

Same journal

Serum Immunofixation Electrophoresis Guidance Conflict: A Call to Harmonize.

Archives of pathology & laboratory medicine·2026

Same journal

In Reply.

Archives of pathology & laboratory medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 5, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Follicular Dendritic Cell Sarcoma.

Tiffany Chen, Purva Gopal¹

¹From the University of Texas, Southwestern Medical School, Dallas (Ms Chen); and the Department of Pathology, University of Texas, Southwestern Medical Center, Dallas (Dr Gopal).

Archives of Pathology & Laboratory Medicine

|March 30, 2017

Summary

This summary is machine-generated.

Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm. This review covers FDCS clinicopathologic features, molecular findings, and treatment, emphasizing its differential diagnosis with spindle cell neoplasms.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Mar 5, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Area of Science:

Oncology
Pathology
Immunohistochemistry

Background:

Follicular dendritic cell sarcoma (FDCS) is a rare tumor.
It typically arises in lymph nodes but can occur extranodally.
FDCS should be considered in the differential diagnosis of spindle cell neoplasms.

Purpose of the Study:

To review the clinicopathologic features of FDCS.
To discuss recent molecular and cytogenetic findings.
To outline current treatment approaches and prognosis.

Main Methods:

Review of existing literature on follicular dendritic cell sarcoma.
Analysis of clinicopathologic, molecular, and cytogenetic data.
Synthesis of information on diagnosis and treatment.

Main Results:

FDCS diagnosis often relies on immunohistochemistry when considered in differential diagnosis.
Recent studies have identified key molecular and cytogenetic alterations.
Prognosis and treatment strategies are evolving.

Conclusions:

A high index of suspicion is crucial for diagnosing FDCS.
Immunohistochemistry is vital for confirming the diagnosis.
Understanding molecular features aids in targeted therapies and prognosis.